A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC

NCT07586202 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Amivantamab
DRUG: Lazertinib
DRUG: Carboplatin
DRUG: Pemetrexed

Sponsor

Janssen Research & Development, LLC